H.Res. 566 119th Congress
Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Latest action, Jul 3, 2025: Motion to reconsider laid on the table Agreed to without objection.
How the House voted: On Agreeing to the Resolution, as Amended
Jul 3, 2025 · Passed · 219–213 (it needed 1/2)
- Yea (219)
- Nay (213)
- Letters: party (D, R, I)
By party
- Democrat
- Republican
- Independent
Every roll call on it (4)
Each dot is a roll call, in order: how much of the House voted yea. The ringed one decided it.
- Carried
- Failed
See the data
| Date | Question | Result | Yea–nay |
|---|---|---|---|
| Jul 3, 2025 | On Agreeing to the Resolution, as Amended | Passed | 219–213 |
| Jul 2, 2025 | On Agreeing to the Amendment | Agreed to | 220–212 |
| Jul 2, 2025 | On Ordering the Previous Question | Passed | 214–212 |
| Jul 2, 2025 | On Consideration of the Resolution | Passed | 212–211 |
Sponsor
Sponsored by Virginia Foxx (Republican). No cosponsors.
Referred to: House: Rules Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
4 reports
All 3 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 5 | $44.6M | Q4 2025 | Q2 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 4 | $5.7M | Q2 2025 | Q2 2026 | yes | |
| THE SUSAN G. KOMEN BREAST CANCER FOUNDATION, INC. DBA SUSAN G. KOMEN | 2 | $310K | Q2 2025 | Q3 2025 | yes |